COVID-19 in Multiple Sclerosis Patients on Long-Term Natalizumab, S1P Agonists and Fumarates

Category Primary study
ConferenceACTRIMS Forum 2025
Year 2025
This article has no abstract
Epistemonikos ID: c298adf65b534b13844b78c5b396304caf4a41de
First added on: Jan 27, 2026